论文部分内容阅读
目的探讨血浆脑利钠肽(BNP)测定在131I治疗甲亢性心脏病(甲心)的应用价值。方法用免疫放射分析法测定血浆脑利钠肽含量,其中甲亢组25例、甲心(NYHA II级)组23例及甲心(NYHAⅢ~Ⅳ级)组15例,健康体检者30例;比较4组患者血浆BNP水平。结果甲心患者治疗前血浆BNP水平均显著高于甲亢组及对照组(P<0.01),甲心(NYHAⅢ~Ⅳ级)组131I治疗前后BNP水平均明显高于同期甲心(NYHAⅡ级)组(P<0.01)。结论血浆BNP水平与心功能受损程度有关,它可作诊断甲心的指标。
Objective To investigate the value of plasma brain natriuretic peptide (BNP) in the treatment of hyperthyroid heart disease (A) by 131I. Methods Plasma levels of brain natriuretic peptide were determined by immuno-radio-immunoassay. Among them, 25 cases were hyperthyroidism, 23 cases were NYHA class II, 15 cases NYHA class Ⅲ and 30 cases were healthy. Plasma BNP level in 4 groups. Results Plasma BNP levels in patients with CHD before treatment were significantly higher than those in hyperthyroidism and control groups (P <0.01). BNP levels in patients with NYHAⅢ ~ Ⅳ before and after 131I treatment were significantly higher than those in NYHA Ⅱ group (P <0.01). Conclusion The plasma BNP level is related to the degree of impaired cardiac function. It can be used as an index for diagnosis of heart failure.